Who Generates More Revenue? Teva Pharmaceutical Industries Limited or Bausch Health Companies Inc.

Teva's Revenue Dominance Over Bausch Health: A Decade in Review

__timestampBausch Health Companies Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014826350000020272000000
Thursday, January 1, 20151049880000019652000000
Friday, January 1, 2016967400000021903000000
Sunday, January 1, 2017872400000022385000000
Monday, January 1, 2018838000000018854000000
Tuesday, January 1, 2019860100000016887000000
Wednesday, January 1, 2020802700000016658000000
Friday, January 1, 2021843400000015878000000
Saturday, January 1, 2022812400000014925000000
Sunday, January 1, 2023875700000015846000000
Monday, January 1, 202416544000000
Loading chart...

Unlocking the unknown

Revenue Race: Teva vs. Bausch Health

In the competitive landscape of pharmaceuticals, revenue generation is a key indicator of a company's market position. Over the past decade, Teva Pharmaceutical Industries Limited has consistently outperformed Bausch Health Companies Inc. in terms of revenue. From 2014 to 2023, Teva's revenue averaged nearly double that of Bausch Health, with Teva peaking in 2017 at approximately 22 billion dollars, while Bausch Health's highest revenue was around 10 billion dollars in 2015.

Despite fluctuations, Teva maintained a strong lead, although both companies experienced a downward trend in recent years. By 2023, Teva's revenue had decreased by about 29% from its 2017 peak, while Bausch Health saw a more modest decline of around 17% from its 2015 high. This data highlights the dynamic nature of the pharmaceutical industry and the challenges companies face in sustaining growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025